We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA faces growing opposition to its newly released drug-labeling rule as Democrats in both chambers consider legislation to prevent the rule from preempting state law. This move follows a threat by state legislators to sue the agency to overturn the rule.
The National Academies’ Institute of Medicine (IOM) will hold its final drug safety meeting this week in preparation for a long-awaited report that observers say could serve as a catalyst for drug safety legislation.
Industry officials are looking beyond a current fight over Congress’ efforts to reduce the federal budget to focus on three key legislative battles in 2006.
Industry officials are looking beyond a current fight over Congress’ efforts to reduce the federal budget to focus on three key legislative battles in 2006.
The Senate narrowly passed a $40 billion budget reconciliation bill Dec. 21, with Vice President Dick Cheney casting the tie-breaking vote, but the measure must still be re-approved by the House after Senate Democrats forced some minor tweaks to the bill.
A $40 billion budget reduction bill that narrowly passed the House Dec. 19 is draw-ing strong criticism from Democrats and senior groups, who contend the legislation spared drug manufacturers from higher costs at the expense of Medicaid and Medicare beneficiaries.
House Democrats contend they have gained initial industry support for legislation introduced Dec. 16 to counter a controversial Republican plan to waive vaccine producers’ liability in the case of a pandemic flu outbreak.
A bipartisan group of House lawmakers is planning a legislative fix to address what they say is government inaction in preventing illegal importation of prescription drugs.
A bipartisan group of House lawmakers is planning a legislative fix to address what they say is government inaction in preventing illegal importation of prescription drugs.
First responders and activists are targeting Sen. Arlen Specter (R-Pa.) in their efforts to prevent a broad vaccine liability waiver from being attached to upcoming appropriations language.